CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Share price
−$0.6913 (−41.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Coherus Oncology, Inc. grew revenue 61.0% to $50.94M over the twelve months to Jun 30, 2026.
Revenue
$50.94M
+61.0% vs. a year earlier
Operating income
-$158.70M
TTM Q2 2026
EPS, diluted
$1.43
+472.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $148.42M
- P/E ratio
- 0.7
- Price to sales
- 2.91
- Price to book
- 2.44
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $50.94M
- Net income
- -$132.13M
- EPS, diluted
- $1.43
- Book value per share
- $0.39
- Diluted shares
- 155M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$50.94M+61.0% YoY
Gross profit
$35.11M+74.6% YoY
Operating income
-$158.70M
Net income
-$132.13M-173.5% YoY
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months